Introduction {#Sec1}
============

Lung infiltrates cause significant morbidity and mortality in immunocompromised patients \[[@CR1], [@CR2]\]. However, this is a heterogeneous group with various aetiology of underlying immunosuppression. The Infectious Diseases Society of America 2013 guidelines has included in its definition of highly immunocompromised patients the following groups: combined immunodeficiency disorder, chemotherapy for cancer, ≤ 2 months post-solid organ transplantation, human immunodeficiency virus (HIV) infection with a CD4 T-lymphocyte count \< 200 cells/mm^3^, daily corticosteroid treatment with a dose ≥20 mg of prednisone or equivalent for ≥14 days and use of biologic immune modulators such as tumor necrosis factor-alpha blockers or rituximab \[[@CR3]\]. Moreover in clinical practice, patients with hematological malignancies or neutropenia and those on steroid-sparing immunosuppressants are also considered immunocompromised.

Despite this heterogeneity of underlying etiology, the majority of these patients with lung infiltrates present in similar manner with cough, fever and dyspnea \[[@CR4]\]. Empiric treatment is not without risks including adverse drug reactions, inadequacy of therapy and development of antimicrobial resistance. Therefore, obtaining a confirmed diagnosis is essential since the therapeutic paradigm varies widely depending on the cause of the lung infiltrates. In addition, early diagnosis has been associated with improved survival, with data reporting confirmed diagnosis within 5 days having a lower mortality compared to later diagnosis (32% vs. 51%, *p* = 0.024) \[[@CR1]\].

Flexible bronchoscopy is commonly used for investigating lung infiltrates because it facilitates collection of microbiological and cytological samples via bronchoalveolar lavage (BAL) and can be performed in an ambulatory setting \[[@CR5]\]. Complications of this procedure include hypoxemia and myocardial ischemia \[[@CR5]\]. Data on diagnostic yield of BAL in immunocompromised patients presenting with lung infiltrates range from 26 to 69%; and complication rates range from 1 to 52% (Table [1](#Tab1){ref-type="table"}). There is marked heterogeneity in the data both in inclusion criteria and study design. This makes it challenging to draw definite conclusions on which patients are most likely to benefit from BAL and on the prognosis of the various groups when categorized according to underlying cause of immunosuppression. In addition, there is limited data from countries where tuberculosis is endemic.Table 1Diagnostic yield and complication rate of BAL in immunocompromised patients presenting with lung infiltrates from a PubMed search since 2000Study designInclusion criteriaBAL Procedures (patient number)Diagnostic yield %Complication rateReichenberger et al., 2001 \[[@CR16]\]RetrospectivePost renal transplant91 (71)69% (63/91)--Hohenadel et al., 2001 \[[@CR13]\]RetrospectiveHematology patients95 (95)65% (62/95)16% (15/95)Rano et al., 2001 \[[@CR17]\]ProspectiveMixed etiology but HIV patients excluded135 (200)51% (68/135)2% (3/135)Taggart et al., 2002 \[[@CR18]\]RetrospectiveHIV patients216 (174)50% (108/216)--Danés et al., 2002 \[[@CR9]\]ProspectiveMixed aetiology including HIV134 (241)52% (70/134)--Jain et al., 2004 \[[@CR19]\]ProspectiveMixed etiology, HIV excluded99 (104)38% (48/125)14% (8/59)Bissinger et al., 2005 \[[@CR20]\]RetrospectiveHematology patients95 (77)56% (53/95)--Peikert et al., 2005 \[[@CR14]\]RetrospectiveNeutropenia35 (35)49% (17/35)9% (3/35)Hofmeister et al., 2006 \[[@CR21]\]RetrospectiveHematopoietic stem cell transplant91 (78)49% (45/91)8% (7/91)Vélez et al., 2007 \[[@CR10]\]ProspectiveMixed aetiology including HIV109 (101)49% (60/122)--Boersma et al., 2007 \[[@CR22]\]ProspectiveHematological malignancy35 (32)26% (9/35)--Burger, 2007 \[[@CR23]\]RetrospectiveHematopoietic stem cell transplant27 (21)52% (14/27)52% (11/21)Cordani et al., 2008 \[[@CR24]\]ProspectiveHematological malignancy25 (24)44% (11/25)--Hummel et al., 2008 \[[@CR25]\]RetrospectiveHematological malignancy246 (199)48% (118/246)1% (3/249)Shannon et al., 2010 \[[@CR26]\]RetrospectiveHematopoietic stem cell transplant598 (501)55% (329/598)12% (74/598)Sampsonas et al., 2011 \[[@CR15]\]ProspectiveMixed etiology but HIV patients excluded284 (284)34% (96/284)4% (10/284)Kottmann et al., 2011 \[[@CR27]\]RetrospectiveMixed etiology190 (190)56% (106/190)--Gilbert et al., 2012 \[[@CR28]\]RetrospectiveHematopoietic stem cell transplant145 (144)53% (77/145)30% (49/162)Brownback et al., 2013 \[[@CR11]\]RetrospectiveMixed aetiology including HIV150 (133)52.5% (79/150)7% (11/150)Kim et al., 2015 \[[@CR29]\]RetrospectiveHematologic malignancy206 (187)65% (134/ 206)--Svensson et al., 2017 \[[@CR30]\]RetrospectiveHematologic malignancy151 (133)39% (59/151)13% (20/151)Sakata et al., 2017 \[[@CR31]\]RetrospectiveHematopoietic stem cell transplant179 (125)40% (71/179)--

The primary objective of this study was to determine the diagnostic yield of BAL in immunocompromised patients presenting with lung infiltrates. Patients who have already progressed to respiratory failure requiring mechanical ventilation have a mortality rate of nearly \> 50% and need to be considered separately \[[@CR1]\]. This population was beyond the scope of our study. Additionally, we aimed to determine the incidence of complications of BAL and identify factors associated with either higher diagnostic yields or lower complication rates. Exploratory aims include characterization of commonly isolated pathogens, the rate of post-procedure treatment modification as an indicator of clinical utility, as well as post-procedure 30 and 90-day mortality. Post-procedure treatment modification reflects the true value of the procedure since some microbiological findings may be of non-pathogenic commensals while other results may not be amendable to clinical intervention. Identification of such data will optimize patient selection, allowing endoscopists to counsel patients and recommend alternative diagnostic modalities for those with low likelihood of successful diagnosis or at high risk of complications.

Materials and methods {#Sec2}
=====================

This retrospective cross-sectional study evaluated immunocompromised patients with radiographic evidence of lung infiltrates who underwent BAL from January 2012 to December 2016 at a tertiary acute care hospital in Singapore. Inclusion criteria was (1) immunocompromised patients, (2) new (≤ 1 month) pulmonary infiltrates on chest radiograph or computed tomography scan, and (3) undergoing flexible bronchoscopy with BAL in an ambulatory setting. Immunocompromised patients were defined according to the Infectious Diseases Society of America 2013 guidelines as highly immunosuppressed or if they had either ongoing haematological malignancy, neutropenia or steroid-sparing immunosuppressant therapy \[[@CR3]\]. Neutropenia severity was categorized based on absolute neutrophil count from mild (1000--1499 per microliter), moderate (500--999 per microliter) and severe (\< 500 per microliter). Exclusion criteria comprised BAL performed in an ICU setting on mechanically ventilated patients, due to differences in procedure such as bronchoscope intubation via an endotracheal tube. Prognosis is also different and poor when the patient has progressed to respiratory failure \[[@CR1]\]. Patients who underwent transbronchial lung biopsies or other forms of bronchoscopic sampling were also excluded to avoid introduction of confounding factors.

Data was extracted from a bronchoscopy database that prospectively collects, via endoscopists' reports, all bronchoscopy details performed at the hospital endoscopy centre. This ensured integrity and completeness of data collection over the study period. Data was rendered non-identifiable with removal of patient's name, identification card number and date of procedure. Chest computed tomography (CT) scans were interpreted by a radiologist and consultant pulmonologist and the predominant abnormalities characterized according to the following categories: consolidation, ground glass opacities, tree-in-bud appearance, reticular infiltrates, nodular infiltrates and cavitation. Institutional review board approval was obtained (SingHealth Centralised Institutional Review Board, reference number: 2011/350/C) and [ClinicalTrials.gov](http://clinicaltrials.gov) identifier is NCT01374542. Waiver of consent was provided by SingHealth Centralised Institutional Review Board.

Procedural details {#Sec3}
------------------

Bronchoscopy was performed using an Olympus BF-1 T160 (Olympus, Tokyo, Japan) bronchoscope that has an outer diameter of 6.0 mm with a 2.8 mm working channel. All procedures were performed under moderate sedation using a combination of fentanyl and midazolam. BAL was obtained from the bronchopulmonary segment corresponding to CT scan findings for focal infiltrates while the right middle lobe or lingular was preferred in the cases with diffuse infiltrates. BAL samples were sent for standardized investigations consisting of cytology and microbiological analysis.

Microscopy for bacteria was performed with Gram stain, acid fast bacilli with Ziehl-Neelsen stain and *Pneumocystis jirovecii* with Gomori methenamine silver. This was followed by bacterial, fungal and mycobacterial cultures. Polymerase chain reaction testing was performed for *Mycobacterium tuberculosis* (TB-Protec) and respiratory viruses: influenza, parainfluenza, respiratory syncytial virus, coronavirus, adenovirus, rhinovirus and metapneumovirus. Cytomegalovirus detected by BAL fluid antigen assay or cell-based virus isolation was considered pathogenic only in the presence of either intracellular inclusion bodies on cytology or concomitant positive serum antigenemia. Galactomannan antigen was performed via enzyme-linked immunosorbent assay.

Outcome measures {#Sec4}
----------------

Primary outcome was diagnostic yield as defined as the number of BAL with a positive diagnostic study divided by the total number of patients. A positive study was defined as either a confirmed diagnosis on cytology or microbiology. Post-BAL treatment modification was considered positive if treatment was documented to be initiated, escalated or discontinued in response to diagnostic BAL findings and if treatment change was in keeping with BAL findings. Patients were followed-up for a minimum of 6 months. Sub-group analysis was performed according to underlying cause of immunosuppression and patients were classified into 3 groups: HIV positive patients, ongoing hematological malignancy and others (HIV negative, non-hematologic malignancy).

Complications were considered associated with bronchoscopy if they occurred peri-procedurally or within 24 h after the patient underwent the procedure. Complication rate was calculated as the number of procedures with complications divided by the total number of procedures performed. Complications were classified into six categories using Common Terminology Criteria for Adverse Events (CTCAE) definitions/severity of pneumothorax, airway bleeding, hypoxia, hypotension and requirement for escalation of level of care \[[@CR6]\].

Statistical analysis {#Sec5}
--------------------

Statistical analyses were performed using statistical software SPSS (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp). Findings were considered statistically significant for all analyses with *p*-value \< 0.05. Continuous variables were summarized using mean (standard deviation, SD) or median (interquartile range, IQR) and categorical variables were summarized using frequency (%). Fisher's exact test and Student's t test or Mann-Whitney U test as appropriate were used to compare categorical and continuous variables respectively. Secondary outcomes were analyzed using logistic regression. Factors with unadjusted odds ratios from univariate logistic regression that satisfied the criteria of *p*-value \< 0.2 were included in multivariable logistic regression analysis to determine the adjusted odds ratios of factors significantly associated with diagnostic yield and complication rate.

Results {#Sec6}
=======

Flexible bronchoscopy with BAL was performed on 217 immunocompromised patients between January 2012 to December 2016. One hundred fifty-two patents (70.1%) were male and the mean age was 51.7 ± 14.6 years. Fifty-nine patients (27.2%) were HIV positive amongst whom 3 had concurrent lymphoma with 2 receiving ongoing chemotherapy. All 59 were analyzed under the HIV category because that was the underlying cause of immunosuppression. A further 92 patients (92/217; 42.4%) had an ongoing hematologic malignancy: 55 with leukemia, 28 with lymphoma, 6 with myelodysplastic syndrome and 3 with multiple myeloma. Among patients with hematologic malignancy, 75 (75/92; 81.5%) had received chemotherapy within the preceding 6 months, 60 patients (60/92; 65.2%) were neutropenic at the time of presentation of pulmonary infiltrates and 19 (19/92; 20.7%) had received hematopoietic stem cell transplants. The remaining 66 (66/217; 30.4%) HIV negative, non-hematologic malignancy patients had immunosuppression due to other causes: of whom 27 received chemotherapy for solid organ malignancies, 15 had solid organ transplants, 38 had received steroid-sparing immunosuppressants and 14 had received high dose corticosteroid therapy.

Fever was the most common presenting symptom (67.3%, 146/217) followed by cough (53.5%, 116/217) and dyspnea (36.4%, 79/217). Median duration of symptoms was 14 days (IQR 8--22.5). Most patients (88.5%, 192/217) received empiric antibiotics prior to bronchoscopy for a median duration of 5 days (IQR 2--10). CT chest scan was obtained in 83.4% (181/217) of patients, with consolidation being the most common finding (66.9%, 121/181) followed by ground glass opacities (51.3%, 93/181). CT scans were performed with a median of 3 days (IQR 2, 5) prior to BAL procedure. Patient characteristics are presented in Table [2](#Tab2){ref-type="table"}. Median duration of bronchoscopy was 10 min (IQR 10--15) and the following sedation was used: median midazolam 2.50 mg (IQR 2.00--3.50) and fentanyl 50 microgram (IQR 25--50). The median volume of BAL fluid instilled was 120 mL (IQR 100--140) and \> 30% of instilled volume was retrieved in 91% of cases (152/167).Table 2Patient characteristicsn (%)Total number of patients217Mean age in years51.7 ± 14.6Male gender152 (70.0%)Current Smokers27 (12.4%)Cause of immunosuppression: HIV/ AIDS59 (27.2%) High dose corticosteroid16 (7.4%) Steroid-sparing immunosuppressive medication44 (20.3%) Solid organ transplant15 (6.9%) Bone marrow transplant33 (15.7%) Hematologic malignancy95 (43.8%)  Leukemia55 (25.3%)  Lymphoma28 (12.9%)  Myelodysplastic syndrome6 (2.8%)  Multiple myeloma3 (1.4%) Chemotherapy104 (47.9%) Neutropenia72 (33.2%)Co-morbidities: Cardiac (e.g. heart failure, ischemic heart disease)9 (4.1%) Pulmonary (e.g. asthma, chronic obstructive pulmonary disease)23 (10.6%) Hepatic (e.g. chronic hepatitis, cirrhosis)21 (9.7%) Renal (e.g. chronic kidney disease)13 (6.0%)Treatment at the time of BAL: Antibiotics192 (88.5%) Median duration, days (IQR)5 (2 - 10) Antivirals103 (47.5%) Antifungals83 (38.2%)Clinical presentation: Fever146 (67.3%) Cough116 (53.5%) Dyspnea79 (36.4%) Pleurisy19 (8.8%) Median symptom duration, days (IQR)14 (8--22.5)Radiologic presentation on CT:*n* = 181 Consolidation121 (66.9%) Ground glass opacities93 (51.3%) Nodules63 (34.8%) Cavitation20 (11.0%) Tree-in-bud appearance18 (9.9%) Reticular pattern11 (6.1%)

Overall diagnostic yield for this study was 60.8% (132/217). Post-procedure treatment modification based on BAL results was 63.3% (84/132). Majority of positive BAL yielded infectious agents (97.0%, 128/132) with 37 cases of *Pneumocystis jirovecii,* 13 *Mycobacteria tuberculosis* and 12 rhinovirus. Cytomegalovirus was found in 16 cases but no inclusion bodies were identified on cytology. Table [3](#Tab3){ref-type="table"} shows all BAL microbiological results. Galactomannan testing was also positive in 31 cases, with ≥0.5 antigen index considered positive. Non-infectious causes of pulmonary infiltrates was found in 4 cases based on cytology and clinical/radiological presentation: eosinophilic pneumonia, squamous cell carcinoma, lung adenocarcinoma and drug-induced pneumonitis. Differences in characteristics of patients with positive and negative BAL are outlined in Table [4](#Tab4){ref-type="table"}.Table 3BAL microbiology resultsn (%)Bacterial Total43  *Mycobacterium tuberculosis*13 (30.2%)  *Pseudomonas aeruginosa*8 (18.6%)  *Klebsiella* spp.5 (11.6%)  *Enterococcus* spp.4 (9.3%)  *Stentotrophomonas maltophilia*4 (9.3%)  *Staphylococcus aureus*2 (4.7%)  *Acinetobacter baumannii*1 (2.3%)  *Escherichia coli*1 (2.3%)  *Mycobacterium abscessus*1 (2.3%)  *Mycobacterium avium*1 (2.3%)  *Nocardia* sp.1 (2.3%)  *Streptococcus pneumoniae*1 (2.3%)  *Streptococcus anginosus*1 (2.3%)Fungal Microscopy/Culture Total51  *Pneumocystis jirovecii*37 (72.5%)  *Aspergillus* spp.10 (19.6%)  *Cryptococcus* spp.3 (5.9%)  *Phaeoacremonium* spp.1 (2.0%)Viral Total64  Cytomegalovirus16 (25.0%)  Rhinovirus12 (18.8%)  Coronavirus9 (14.1%)  Parainfluenza9 (14.1%)  Influenza7 (10.9%)  Respiratory syncytial virus7 (10.9%)  Adenovirus3 (4.7%)  Metapneumovirus1 (1.6%)Table 4Factors impacting BAL diagnostic yield (^\*^*p* \< 0.05)Negative BAL n (%)Positive BAL n (%)p-valueTotal85 (39.2%)132 (60.8%)Male gender54 (63.5%)98 (74.2)0.098Mean age in years ± SD52.4 ± 14.651.3 ± 14.60.588Current smokers10 (11.8%)17 (12.9%)1.000Cause of immunosuppression: HIV/ AIDS12 (14.1%)47 (35.6%)0.001^\*^ High dose corticosteroids8 (9.4%)8 (6.1%)0.428 Steroid-sparing immunosuppressive medication17 (20.0%)27 (20.5%)1.000 Hematologic malignancy46 (54.1%)49 (37.1%)0.017^\*^  Leukemia30 (35.3%)25 (18.9%)0.010^\*^  Lymphoma14 (16.5%)17 (12.9%)0.552  Myelodysplastic2 (2.4%)4 (3.0%)1.000  Multiple myeloma0 (0%)3 (2.3%)0.282 Chemotherapy54 (63.5%)50 (37.9%)\< 0.001^\*^ Neutropenia32 (37.6%)40 (21.6%)0.302  Mild (ANC 1000--1499/μl)8 (9.6%)4 (3.1%)0.127  Moderate (ANC 500--999/μl)7 (8.4%)6 (4.6%)  Severe (ANC \< 500/μl)16 (19.3%)29 (22.1%)Clinical presentation: Fever60 (74.1%)86 (65.6%)0.224 Cough38 (46.9%)78 (59.5%)0.089 Dyspnea26 (32.1%)53 (40.5%)0.244 Pleurisy7 (8.6%)12 (9.2%)1.000Median symptom duration in days (IQR)15 (8--66)19 (11--65.5)0.017^\*^Treatment at the time of BAL: Antibiotics75 (90.4%)117 (90.0%)1.000 Median duration antibiotics in days (IQR)7 (4, 10)6 (3, 11)0.477 Antifungals33 (38.8%)50 (37.9%)0.887 Antivirals43 (50.6%)60 (45.5%)0.488Radiologic presentation on CT (*n* = 181): Consolidation44 (54.3%)57 (57.0%)0.764 Ground glass opacities42 (51.9%)51 (51.0%)1.000 Tree-in-bud appearance11 (13.6%)7 (7.0%)0.211 Reticular pattern3 (3.7%)8 (8.0%)0.350 Nodules32 (39.5%)31 (31.0%)0.273 Cavitation6 (7.5%)14 (14.0%)0.233BAL segments: Upper lobes44 (51.8%)62 (47.7%)0.579 Right middle lobe26 (30.6%)32 (24.6%)0.350 Lower lobes32 (37.6%)53 (40.8%)0.671

In multivariable logistic regression analysis, factors significantly associated with higher diagnostic yield included HIV infection (adjusted OR 5.304, 95% CI 1.611--17.458, *p* = 0.006), severe neutropenia (adjusted OR 4.253, 95% CI 1.288--14.045, *p* = 0.018) and presence of cavitatory lesions on chest CT scan (adjusted OR 3.824, 95% CI 0.877--16.680, *p* = 0.074). In addition, leukaemia as an underlying cause of immunosuppression was significantly associated with lower diagnostic yield (adjusted OR 0.317, 95% CI 0.102--0.982, *p* = 0.047) (See supplementary materials in [Appendix 1](#Sec10){ref-type="sec"}). In univariate analysis, haematological malignancy (unadjusted OR 0.501, 95% CI 0.288--0.871, *p* = 0.014) and ongoing chemotherapy at the time of the scope (unadjusted OR 0.350, 95% CI 0.199--0.616, *p* \< 0.001) had a lower diagnostic yield ([Appendix 1](#Sec10){ref-type="sec"}).

Overall complication rate for this study was 14.7% (32/217) with 94% (30/32) attributable to self-limiting hypoxemia that required supplemental oxygen therapy temporarily (CTCAE 2). The remaining two cases were of endobronchial bleeding that did not require further endoscopic intervention (CTCAE 1). Both patients were thrombocytopenic with platelet counts of 27,000 per microliter and 126,000 per microliter. No patients required intubation or escalation of care. Post-procedure 30-day and 90-day mortality was 10.6% (23/217) and 17.5% (38/217) respectively. Patients who suffered complications had significantly higher median Charlson comorbidity index (median 5, IQR 3--7) compared to those who did not suffer complications (median 4, IQR 3--6; *p* = 0.011) \[[@CR7]\]. Univariate logistic regression analysis for complication rate found dyspnea during disease presentation to be significantly associated with increased complications (unadjusted OR 2.508, 95% CI 1.169--5.382, *p* = 0.018). Multivariable logistic regression analysis found no factors significantly associated with complication rate (See supplementary material in [Appendix 2](#Sec11){ref-type="sec"}).

Subgroup analyses {#Sec7}
-----------------

Diagnostic yield of BAL in HIV patients was 79.7% (47/59) of which the majority of positive diagnoses was of *Pneumocystis jirovecii* (70.2%, 33/47). Other diagnoses included 4 cases of *Mycobacteria tuberculosis*, 4 rhinovirus and 3 *Aspergillus* species. Despite the high diagnostic yield, only 40.4% (19/47) of BAL results in HIV directly impacted patient management. Complication rate was 20.3% (12/59) all of which was attributable to hypoxemia requiring supplemental oxygen. Post-procedure 30-day and 90-day mortality was 1.7% (1/59) and 6.8% (4/59) respectively.

In non-HIV, hematologic malignancy patients diagnostic yield was 51.1% (47/92) and of these 70.2% (33/47) of cases impacted patient management with treatment modification. Isolated pathogens included 8 cases of parainfluenza virus, 5 *Pseudomonas aeruginosa*, 4 rhinovirus, 4 respiratory syncytial virus, 3 *Mycobacterium tuberculosis*, 3 *Klebsiella* species and 3 coronavirus. Complication rate was 10.9% (10/92), while post-procedure 30-day and 90-day mortality was 17.4% (16/92) and 28.3% (26/92) respectively. Mortality rate was significantly higher for non-HIV, hematologic malignancy patients than for HIV and for non-HIV, non-hematologic malignancy groups.

In non-HIV, non-hematologic malignancy patients diagnostic yield was 57.6% (38/66), with 84.2% (32/38) of these resulting in modification of therapy. Pathogens included 6 cases of *Mycobacterium tuberculosis*, 5 human coronavirus, 5 *Aspergillus* species, 4 *Pneumocystis jirovecii*, 4 rhinovirus and 3 cases of *Pseudomonas aeruginosa*. Complication rate was 15.2% (10/66) and post-procedure 30-day and 90-day mortality was 9.1% (6/66) and 12.1% (8/66) respectively. Test of proportions indicated that mortality rate was significantly different in at least one category (HIV patients, non-HIV hematologic malignancy patients or non-HIV, non-hematologic malignancy patients) compared to the others (*p* = 0.008).

Discussion {#Sec8}
==========

The diagnostic yield of BAL in immunocompromised patients presenting with lung infiltrates in an ambulatory setting was 60.8% and in the majority of cases, the positive BAL findings impacted clinical management. Infectious etiologies accounted for 97% of the positive diagnoses which reinforces current clinical practice of early use of empiric antibiotics. In addition, our study found no impact of prior anti-microbial therapy or duration of antibiotics on diagnostic yield. The mismatch between positive yield and post-BAL result treatment modification may be attributable to the fact that 40.5% (64/158) of pathogens detected were respiratory viruses for which therapeutic options were limited. In addition, in none of the 16 isolates of cytomegalovirus was there inclusion bodies detected in the corresponding cytology. This raises doubts over the pathogenic nature of the cytomegalovirus isolates. Cases where the BAL cytomegalovirus isolate was the only finding (including no antigenemia) were not labelled as positive diagnostic yield. There were 17.1% (37/217) cases of *Pneumocystis jirovecii*, 6.0% (13/217) cases of tuberculosis, 4.6% (10/217) cases of Aspergillosis and 3.7% (8/217) cases of *Pseudomonas* infection. In addition, in 14.3% (31/217) BAL Galactomannan was positive.

We also showed differences in the diagnostic yield between different groups based on causes of underlying immunosuppression. HIV patients had the highest diagnostic yield and the majority of positive *Pneumocystis jirovecii* results identified were in this group. It also meant that post-BAL treatment modification was the lowest in this group because Pneumocystis pneumonia was often the clinical diagnosis and appropriate empiric treatment had already been commenced. There was also a trend towards increased risk of post procedure hypoxia in HIV patients which endoscopists should note with respect to ensuring appropriate post-procedure monitoring. Previous data on HIV patients showed a diagnostic yield of 50--60% \[[@CR8]\], and mixed groups with HIV patients showed yields of 49 to 52.5% \[[@CR9]--[@CR11]\].

In contrast, the diagnostic yield was lower in patients with hematologic malignancy, especially those with leukaemia. There are possible explanations for this. Non-infective aetiology such as alveolar haemorrhage may be more prevalent in this group. BAL can only procure cytological and not histological specimens for analysis. Other conditions such as drug induced pneumonitis may not have pathognomonic findings and it may be difficult to establish a confirmed cause when it is a diagnosis of exclusion. Therefore, alternative sampling including lung biopsies should be considered early in patients with hematologic malignancies.

Non-HIV, non-hematologic malignancy patients had a diagnostic yield that was in between the HIV patient and hematologic malignancy group. The most pertinent finding in this group was that the most commonly identified pathogen was *Mycobacteria tuberculosis*. This may be reflective of the endemic nature of tuberculosis in our population in Singapore \[[@CR12]\], as well as the nature of the immunosuppression. This finding is corroborated by the presence of radiological evidence of cavitation in 11% of our patients and the trend towards increased diagnostic yield if cavitation was indeed present.

Complication rate was significant at 14.7% but was entirely self-limiting. There was a trend towards a higher rate in patients with higher co-morbidity burden and in those who were hypoxic at presentation. Co-morbidities are likely to impact the effect of moderate sedation on the cardio-respiratory system. Hypoxemia may be exacerbated by the introduction of saline for lavage and the degree of decruitment from bronchoscopic suctioning.

Our study also confirmed earlier data that prognosis of immunocompromised patient with pulmonary infiltrates was guarded and varied with underlying cause of immunosuppression. The all-cause 30-day and 90-day mortality ranged from 1.7 and 6.8% in HIV patients to 17.4 and 28.3% respectively in those with hematologic malignancy. Prior data showed a 30-day mortality in haematology patients to be 22% \[[@CR13]\] and in neutropenic patients to be 26% \[[@CR14]\]. In a mixed aetiology study, the 30-day mortality was 7% in non-hematologic malignancy and 19% with hematologic malignancy \[[@CR15]\]. This reflects the severity of illness that immunocompromised patients with pulmonary infiltrates have and should serve as an impetus to continue to improve bronchoscopic sampling and laboratory testing. Symptoms and radiological findings (besides the trend in presence of cavitation) also did not impact diagnostic yield in our study. Therefore, identifying patients who are unlikely to get a bronchoscopic diagnosis on the basis of only clinical presentation may be challenging. Delaying diagnosis due to a negative BAL result may also risk clinical deterioration.

Limitations of this study include the retrospective design. However, the fact that the data was extracted from a prospective bronchoscopy database directly populated by endoscopists' reports ensured completeness of data. In addition, procedure details were collected in a standardized format. Sample size may also have lacked statistical power to detect factors associated with complications because of the low complication rate. Finally, this data was limited to a single institution study. However, this meant that BAL sampling and microscopic testing was performed in a standardized manner.

Conclusion {#Sec9}
==========

Flexible bronchoscopy with BAL retains a role in the management of immunocompromised patients presenting with lung infiltrates especially in establishing a confirmed microbiological diagnosis. A diagnosis is possible in 60.8% and the complications are largely self-limiting. However, the diagnostic yield varies with underlying cause of immunosuppression and alternative sampling should be considered early in patients with hematologic malignancies because of poor results with BAL. This group with haematologic malignancy has a high 90-day mortality and delayed diagnosis risk clinical deterioration. Tuberculosis appears to be an important pathogen in endemic regions especially in the non-HIV, non-hematologic malignancy group. Aspergillus was the other commonly identified pathogen via culture and Galactomannan assay. Viruses accounted for 40.5% of positive diagnosis and this finding often leads to limited modification in clinical management. Our data show both the utility and limitations of BAL in the approach to immunocompromised patients presenting with lung infiltrates. This data will serve as the foundation on which newer therapeutic strategies such as transbronchial cryobiopsy can be evaluated.

Appendix 1 {#Sec10}
==========

Table 5Univariate and multiple logistic regression for diagnostic yield (^\*^*p* \< 0.05)Univariate OR\
(95% CI)*p*-valueMultiple OR\
(95% CI)*p*-valueMale Gender1.655 (0.918--2.983)0.094Mean age in years0.995 (0.976--1.014)0.586Current smokers1.109 (0.482--2.552)0.808Cause of immunosuppression: High dose corticosteroids0.621 (0.224--1.723)0.360 HIV/ AIDS3.364 (1.659--6.820)0.001^\*^5.304 (1.611--17.458)0.006^\*^ Steroid-sparing immunosuppressive medication1.029 (0.522--2.029)0.935 Solid organ transplant0.963 (0.330--2.811)0.946 Bone marrow transplant1.217 (0.567--2.610)0.614 Hematologic malignancy0.501 (0.288--0.871)0.014^\*^  Leukemia0.428 (0.230--0.798)0.008^\*^0.317 (0.102--0.982)0.047^\*^  Lymphoma0.750 (0.348--1.614)0.461  Myelodysplastic1.297 (0.232--7.240)0.767  Multiple myelomaN.A.N.A. Chemotherapy0.350 (0.199--0.616)\< 0.001^\*^ Neutropenia0.720 (0.405--1.279)0.263Severity (Reference no neutropenia) Mild (ANC 1000--1500/μl)0.283 (0.081--0.984)0.0470.249 (0.42--1.460)0.123 Moderate (ANC 500--999/μl)0.214 (0.155--1.518)0.2141.749 (0.385--7.942)0.469 Severe (ANC \< 500/μl1.024 (0.509--2.060)0.9464.253 (1.288--14.045)0.018^\*^Clinical Presentation: Fever0.669 (0.362--1.236)0.199 Cough1.665 (0.952--2.912)0.074 Dyspnea1.437 (0.803--2.574)0.222 Pleurisy1.066 (0.402--2.830)0.898 Symptom duration1.021 (1.001--1.042)0.039Treatment at the time of BAL: Antibiotics0.960 (0.380--2.426)0.931 Duration of antibiotics0.995 (0.964--1.028)0.784 Antifungals0.961 (0.549--1.683)0.889 Antivirals0.814 (0.471--1.405)0.460Radiologic Presentation on CT: Consolidation1.115 (0.618--2.010)0.718 Ground glass opacities0.966 (0.538--1.737)0.909 Tree-in-bud appearance0.479 (0.177--1.298)0.148 Reticular pattern2.261 (0.580--8.815)0.240 Nodules0.688 (0.372--1.272)0.233 Cavitation2.031 (0.743--5.554)0.1673.824 (0.877--16.680)0.074Segments: Upper lobes0.850 (0.492--1.468)0.559 Right middle lobe0.741 (0.403--1.364)0.335 Lower lobes1.140 (0.650--1.998)0.647Number of pulmonary segments sampled: ≥ 2 (reference one segment)0.516 (0.270--0.987)0.045^\*^0.347 (0.125--0.965)0.043^\*^

Appendix 2 {#Sec11}
==========

Table 6Univariate and multiple logistic regression for risk of BAL complications (^\*^*p* \< 0.05)Univariate OR\
(95% CI)*p*-valueMultiple OR\
(95% CI)*p*-valueMale gender2.029 (0.793--5.194)0.140Mean age in years0.986 (0.961--1.011)0.263Current smokers1.372 (0.479--3.933)0.556Cause of immunosuppression: High dose corticosteroids0.366 (0.47--2.869)0.338 HIV/ AIDS1.762 (0.801--3.876)0.159 Steroid-sparing immunosuppressive medication1.120 (0.450--2.789)0.808 Solid organ transplant1.491 (0.396--5.610)0.554 Bone marrow transplant0.738 (0.241--2.258)0.595 Hematologic malignancy0.535 (0.240--1.192)0.126  Leukemia0.500 (0.182--1.370)0.178  Lymphoma0.580 (0.165--2.034)0.395  MyelodysplasticN.A.N.A.  Multiple myeloma12.267 (1.079--139.514)0.043^\*^ Chemotherapy0.821 (0.386--1.748)0.609 Neutropenia0.902 (0.402--2.022)0.802Severity (reference no neutropenia) Mild (ANC 1000--1500/ml)1.848 (0.464--7.372)0.384 Moderate (ANC 500--999/ml)0.462 (0.057--3.736)0.469 Severe (ANC \< 500/ml)0.853 (0.323--2.255)0.749Comorbidities Diabetes mellitus0.893 (0.343--2.324)0.816 Cardiac0.714 (0086--5.908)0.754 Pulmonary1.248 (0.395--3.942)0.706 Hepatic1.412 (0.442--4.505)0.560 Renal1.810 (0.470--6.974)0.388Charlson comorbidity index1.108 (0.948--1.295)0.196Clinical Presentation: Fever1.184 (0.515--2.722)0.690 Cough1.708 (0.778--3.749)0.182 Dyspnea2.508 (1.169--5.382)0.018^\*^ Pleurisy0.639 (0.140--2.911)0.563 Duration of symptoms1.005 (0.988--1.022)0.592Treatment at the time of BAL: AntibioticsN.A.N.A. Duration of Antibiotics0.960 (0.903--1.021)0.195 Antifungals0.489 (0.208--1.146)0.100 Antivirals0.839 (0.394--1.786)0.649Radiologic presentation on CT: Consolidation1.417 (0.610--3.292)0.418 Ground glass opacity2.107 (0.891--4.980)0.090 Tree-in-bud appearanceN.A.N.A. Reticular pattern2.281 (0.565--9.208)0.247 Nodules0.376 (0.135--1.048)0.0610.391 (0.140--1.093)0.074 Cavitation0.596 (0.130--2.728)0.505Duration of procedure in minutes1.009 (0.954--1.068)0.742Dose of midazolam in milligram1.001 (0.999--1.004)0.386Dose of fentanyl in microgram1.002 (0.987--1.018)0.792Segments: Upper lobes0.892 (0.420--1.893)0.766 Right middle lobe0.725 (0.295--1.779)0.482 Lower lobes1.227 (0.574--2.621)0.597Number of pulmonary segments sampled: ≥ 2 (reference one segment)0.701 (0.301--1.633)0.410

BAL

:   Bronchoalveolar lavage

CI

:   Confidence interval

CT

:   Computed tomography

CTCAE

:   Common Terminology Criteria for Adverse Events

HIV

:   Human immunodeficiency virus

ICU

:   Intensive care unit

IQR

:   Interquartile range

OR

:   Odds ratio

SD

:   Standard deviation
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